{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Seagen%2C+a+wholly+owned+subsidiary+of+Pfizer", "query": { "sponsor": "Seagen, a wholly owned subsidiary of Pfizer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Seagen%2C+a+wholly+owned+subsidiary+of+Pfizer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T02:23:38.230Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Esophageal Adenocarcinoma", "Cholangiocarcinoma", "Gallbladder Carcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430738" }, { "nct_id": "NCT04404283", "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 239, "start_date": "2020-08-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Bonita Springs", "state": "Florida" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04404283" }, { "nct_id": "NCT04569032", "title": "A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2020-11-12", "completion_date": "2026-01-12", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04569032" }, { "nct_id": "NCT03975647", "title": "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-positive Breast Cancer" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 466, "start_date": "2019-10-02", "completion_date": "2029-03-10", "has_results": true, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 321, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03975647" }, { "nct_id": "NCT05983133", "title": "A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Squamous Cell Carcinoma of the Head and Neck", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "PF-08046052", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2023-11-14", "completion_date": "2026-04-16", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 22, "location_summary": "Los Angeles, California • Santa Monica, California • Tampa, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05983133" }, { "nct_id": "NCT04227847", "title": "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "SEA-CD70", "type": "DRUG" }, { "name": "azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2020-08-07", "completion_date": "2028-07-03", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04227847" }, { "nct_id": "NCT05208762", "title": "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Squamous Cell Carcinoma of the Head and Neck", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Neoplasms", "Gastric Cancer", "Endometrial Cancer", "Pancreatic Adenocarcinoma", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "PF-08046054", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 714, "start_date": "2022-10-25", "completion_date": "2029-01-04", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Irvine, California • Orange, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05208762" }, { "nct_id": "NCT05253651", "title": "A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "levoleucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2022-10-24", "completion_date": "2030-07-03", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 132, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 82 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05253651" }, { "nct_id": "NCT06120504", "title": "A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, T-Cell, Cutaneous", "Hodgkin Disease", "Lymphoma, T-Cell, Peripheral", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "PF-08046045", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2024-02-29", "completion_date": "2025-12-10", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 15, "location_summary": "Palo Alto, California • Coral Gables, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120504" }, { "nct_id": "NCT04697628", "title": "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "tisotumab vedotin", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "vinorelbine", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 502, "start_date": "2021-02-22", "completion_date": "2026-01-15", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-08T02:23:38.230Z", "location_count": 53, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697628" } ] }